Artiva Biotherapeutics raises ~$300M in common stock and pre-funded warrant offering

Artiva Biotherapeutics, Inc.

Priced 23,871,526 shares at $11.52/share and 2,170,138 pre-funded warrants at $11.5199 each.
Gross proceeds ~$300M before underwriting discounts and expenses.
Offering managed by Jefferies, TD Securities, and Cantor Fitzgerald; closing expected May 11, 2026.
Pre-funded warrants exercisable immediately with 4.99% beneficial ownership cap; cap can be increased to 19.99%.
Company registered under S-3; shares and warrants listed on Nasdaq under ARTV.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.